Clinical Trial Update: The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating zoledronic acid in men with prostate cancer on androgen deprivation therapy who have preexisting osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Prostate Cancer

Drugs mentioned

• RECLAST (ZOLEDRONIC ACID)
• Zometa (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED